Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
KNC Laboratories Co., Ltd. (6568.T)
JPY1,320.00
-10.00 (-0.75%)
JP JPX Basic Materials Chemicals
Address
7-1-19 Minatojimaminamimachi 650-0047
Kobe, JP
Kobe, JP
CEO
Takuya Maoka
Website
kncweb.co.jp
IPO
2018-03-15
ISIN JP3290400005
Description
Established in 1985 and headquartered in Kobe, Japan, KNC Laboratories Co., Ltd. focuses on the innovation, creation, and fabrication of organic chemical products. Their extensive range of offerings is utilized across various industries, including pharmaceuticals, electronic chemistry, agrochemicals, energy, and environmental management. Furthermore, the company provides critical support services for both medicinal compounds and advanced functional chemicals.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY1,320.00
-10.00 (-0.75%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4.8K
Beta
0.35
Float Shares
2.84M
Free Float %
36.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.18% | -12.04% | -7.21% | -10.58% | +3.47% | -1.31% | +13.77% | -23.82% | -20.62% | -69.97% | -69.97% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,320.00
DCF (Levered)
6,554.05
+396.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
MOAT Score
1 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Chemicals: +4.0%+11.2% ★
-
EPS growth Chemicals: +11.7%+3.8%
-
FCF margin FCF growth · Chemicals: +41.7%+11.3%
-
EBIT margin Chemicals: +7.1%+11.3% ★
-
ROIC Chemicals: +3.4%+4.9% ★
-
Share dilution Chemicals: +0.0%+0.1%
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×1.59×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.29B
est: 6.30B (-0.1%)
|
6.35B
est: 5.90B (+7.6%)
|
6.03B
est: 5.85B (+3.1%)
|
7.44B
est: 7.44B (+0.0%)
|
8.63B
est: 8.30B (+4.0%)
|
9.15B
est: 9.30B (-1.6%)
|
8.18B
est: 9.10B (-10.1%)
|
10.00B
10.00B – 10.00B
+9.9% YoY
|
12.00B
12.00B – 12.00B
+20.0% YoY
|
| EBITDA |
2.00B
est: 1.79B (+11.7%)
|
1.38B
est: 1.67B (-17.6%)
|
1.58B
est: 1.66B (-5.0%)
|
2.02B
est: 2.11B (-4.0%)
|
3.08B
est: 2.35B (+31.0%)
|
3.00B
est: 2.64B (+13.7%)
|
1.65B
est: 2.56B (-35.5%)
|
2.82B
2.82B – 2.82B
+9.9% YoY
|
3.38B
3.38B – 3.38B
+20.0% YoY
|
| EBIT |
1.24B
est: 1.04B (+19.8%)
|
574.46M
est: 969.83M (-40.8%)
|
635.47M
est: 961.61M (-33.9%)
|
1.09B
est: 1.22B (-10.5%)
|
2.16B
est: 1.36B (+58.6%)
|
2.08B
est: 1.18B (+75.7%)
|
771.86M
est: 1.51B (-49.0%)
|
1.66B
1.66B – 1.66B
+9.9% YoY
|
2.00B
2.00B – 2.00B
+20.0% YoY
|
| Net Income |
936.35M
est: 830.68M (+12.7%)
|
518.48M
est: 459.00M (+13.0%)
|
399.68M
est: 308.32M (+29.6%)
|
643.46M
est: 638.27M (+0.8%)
|
1.54B
est: 1.33B (+15.7%)
|
1.49B
est: 1.47B (+1.5%)
|
737.33M
est: 1.05B (-29.9%)
|
1.12B
1.12B – 1.12B
+6.7% YoY
|
1.61B
1.61B – 1.61B
+43.8% YoY
|
| SGA |
731.64M
est: 824.17M (-11.2%)
|
861.48M
est: 771.84M (+11.6%)
|
762.56M
est: 765.30M (-0.4%)
|
841.00M
est: 973.30M (-13.6%)
|
954.92M
est: 1.09B (-12.1%)
|
1.05B
est: 1.11B (-5.6%)
|
1.08B
est: 1.13B (-4.1%)
|
1.24B
1.24B – 1.24B
+9.9% YoY
|
1.49B
1.49B – 1.49B
+20.0% YoY
|
| EPS |
121.29
est: 107.50 (+12.8%)
|
67.02
est: 59.40 (+12.8%)
|
51.54
est: 39.90 (+29.2%)
|
82.78
est: 82.60 (+0.2%)
|
200.06
est: 172.50 (+16.0%)
|
193.50
est: 190.40 (+1.6%)
|
95.42
est: 136.00 (-29.8%)
|
145.10
145.10 – 145.10
+6.7% YoY
|
208.60
208.60 – 208.60
+43.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
Ownership data is not available for this company yet.
Executive team
Top executives
EBIT / Employee
4.68M
Shares Outstanding
7.74M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hidemi Yoshida | GM of Fine Chemicals Quality Assurance Dept., Director of Fine Chemical Division & Director | — | — |
| Jun-ichi Miyahara | Corporate Officer, Head of Bio Business Division & Head of Bio Quality Assurance | — | — |
| Kimihiro Kamasaka | GM of Functional Materials Division & Director | — | male |
| Koji Matsuo | Corporate Officer & GM of Procurement Dept. | — | — |
| Masahiro Neya | Mana Off of Pharmaceutic. Busi, GM of Quality Assurance Dept., Executive MD & Director | — | male |
| Ryuichi Inoue | GM of Corporation Strategy Department, Managing officer of HR & Director | — | — |
| Satoshi Kobayashi | Corporate Officer & Director of Pharmaceutical Division | — | — |
| Takamitsu Nagakawa | Corporate Officer and Director of Sales & Marketing Division | — | — |
| Takuya Maoka | CEO, GM of Administration, President & Representative Director | — | male |
| Yasuhide Kuriyama | GM of Gen. Affairs Department, Managing officer of Fin. and Accounting & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6568.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
